In the last week, the FDA approved the first maternal vaccine designed to safeguard infants from respiratory syncytial virus (RSV) during the critical period immediately from birth up to 6 months of age, when they are most vulnerable to infection.
RSV, a highly contagious respiratory virus, poses a considerable threat to infants, particularly those under the age of 6 months. Infants in this age group are at an elevated risk of experiencing severe RSV-related illnesses, including bronchiolitis, pneumonia, and the need for hospitalization. In fact, statistics show that between 75% and 80% of infants requiring hospitalization due to RSV do so within the first 6 months of their lives.
Pfizer’s ABRYSVO may offer a protective shield against the potentially severe consequences of RSV during the initial 6 months of a baby’s life. This vaccine is administered between the 32nd and 36th weeks of pregnancy. Its mechanism of action involves fortifying the mother’s immune system, enabling her to pass on this protective immunity to her unborn baby. Consequently, upon birth, the baby possesses its mother’s antibodies, which play a crucial role in shielding them from RSV.
CenExel JBR, located in Salt Lake City, UT, actively participated in the clinical trials that underpinned the development of this vital vaccine. We take immense pride in contributing to this groundbreaking research, which is poised to save the lives of countless infants worldwide.
For more information on how CenExel can support your vaccine clinical trials, please visit www.cenexel.com!